JAMA: SARS-CoV-2 vaccine safe during pregnancy

Studies have reported that pregnant women are at higher risk for severe COVID-19
.

Therefore, the U.

Studies have reported that pregnant women are at higher risk for severe COVID-19

Maria C.

The study enrolled 157,521 singleton pregnancies ending after 22 weeks of gestation
.

Vaccination records were collected for mRNA vaccines BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) and 1 viral vector vaccine AZD1222 (AstraZeneca)

The study enrolled 157,521 singleton pregnancies ending after 22 weeks of gestation

Of the 157,521 singleton deliveries included in the study (103,409 in Sweden and 54,112 in Norway), the mean maternal age at delivery was 31 years, and 28,506 (18%) were vaccinated with SARS-CoV-2 (12.

Cumulative incidence curve of preterm birth, very preterm birth and stillbirth risk according to SARS-CoV-2 vaccination

Cumulative incidence curve of preterm birth, very preterm birth and stillbirth risk according to SARS-CoV-2 vaccination

Vaccination with SARS-CoV-2 and preterm birth (6.
2 vs 4.
9 per 10 000 gestation days; adjusted hazard ratio [aHR], 0.
98 [95% CI, 0.
91 to 1.
05]; I ² = 0%; P for heterogeneity = .
60), stillbirth (2.
1 vs 2.
4 per 100 000 gestation days; aHR, 0.
86 [95% CI, 0.
63 to 1.
17]), preterm birth (7.
8% vs 8.
5%; difference, -0.
6% [95% CI, -1.
3% to 0.
2%]; adjusted OR [aOR], 0.
97 [95% CI, 0.
90 to 1.
04]), low Apgar score ( 1.
5% vs 1.
6% ; difference, -0.
05% [95% CI, -0.
3] % to 0.
1%]; aOR, 0.
97 [95% CI, 0.
87 to 1.
08]) or neonatal care admission (8.
5% vs 8.
5%; difference, 0.
003% [95% CI, -0.
9% to 0.
9%]; aOR, 0.
97 [95% CI, 0.
86 to 1.
10]) was not significantly associated with an increased risk
.

Vaccination with SARS-CoV-2 and preterm birth Vaccination with SARS-CoV-2 and preterm birth (6.
2 vs 4.
9 per 10 000 gestation days; adjusted hazard ratio [aHR], 0.
98 [95% CI, 0.
91 to 1.
05]; I ² = 0%; P = .
60 for heterogeneity), ² stillbirths (2.
1 vs 2.
4 per 100 000 gestation days; aHR, 0.
86 [95% CI, 0.
63 to 1.
17]), 2 stillbirths ( 7.
8% vs 1.
17) 8.
5%; difference, -0.
6% [95% CI, -1.
3% to 0.
2%]; adjusted OR [aOR], 0.
97 [95% CI, 0.
90 to 1.
04]), Apgar Apgar score low score ( 1.
5% vs 1.
6% ; difference, -0.
05% [95% CI, -0.
3% to 0.
1%]; aOR, 0.
97 [95% CI, 0.
87 to 1.
08]) or neonatal care admission (8.
5% vs 8.
5%; difference, 0.
003 % [95% CI, -0.
9% to 0.
9%]; aOR, 0.
97 [95% CI, 0.
86 to 1.
10]) No significant association with increased risk No significant association with increased risk .

Odds ratios for low 5-minute Apgar score, preterm infants, and hospitalization for neonatal care based on SARS-CoV-2 vaccination during pregnancy

Odds ratios for low 5-minute Apgar score, preterm infants, and hospitalization for neonatal care based on SARS-CoV-2 vaccination during pregnancy

In this population-based study conducted in Sweden and Norway, SARS-CoV-2 vaccination during pregnancy was not significantly associated with an increased risk of adverse pregnancy outcomes compared with no SARS-CoV-2 vaccination during pregnancy
.

In this population-based study conducted in Sweden and Norway, SARS-CoV-2 vaccination during pregnancy was not significantly associated with an increased risk of adverse pregnancy outcomes compared with no SARS-CoV-2 vaccination during pregnancy
.

SARS-CoV-2 vaccination during pregnancy was not significantly associated with an increased risk of adverse pregnancy outcomes compared with no SARS-CoV-2 vaccination during pregnancy

Magnus MC, Örtqvist AK, Dahlqwist E, et al.

Association of SARS-CoV-2 Vaccination During Pregnancy With Pregnancy Outcomes.

Magnus MC, Örtqvist AK, Dahlqwist E, et al.
Association of SARS-CoV-2 Vaccination During Pregnancy With Pregnancy Outcomes.
  JAMA.
Leave a Comment